EPISODE · Apr 29, 2020 · 26 MIN
Chasing Wellness: Gilead’s Remdesivir & Tools for Healthy Isolation
from Squawk Pod · host CNBC
A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
A new study from the NIAID revealed that at least 50% of Covid-19 patients treated with a 5-day dosage of Gilead’s Remdesivir reported improved symptoms and were discharged from the hospital within two weeks. Former FDA Commissioner Dr. Scott Gottlieb describes the treatment as “part of a better toolbox” for fighting the coronavirus, but “not a home run.” Plus, Mindy Grossman, CEO of WW International, (formerly known as Weight Watchers) discusses keeping her business and our bodies well during quarantine.
NOW PLAYING
Chasing Wellness: Gilead’s Remdesivir & Tools for Healthy Isolation
No transcript for this episode yet
Similar Episodes
Mar 14, 2026 ·23m
Mar 11, 2026 ·16m
Feb 28, 2026 ·14m